Merrick I. Ross
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Merrick I. Ross has a total of 131 co-authors. Here are the top co-authors by number of shared publications:
- Craig L. Slingluff
Department of Surgery/Division of Surgical Oncology and the Human Immune Therapy Center, Cancer Center, University of Virginia, Charlottesville, USA
18 shared publications - Hong Zhu
Department of Public Health Sciences, University of Virginia , Charlottesville, Virginia
18 shared publications - Kimberly A. Chianese-Bullock
University of Virginia 2 Charlottesville, Virginia
18 shared publications - Margaret von Mehren
Fox Chase Cancer Center, Philadelphia, PA
18 shared publications - Amrita Sarkar
University of Virginia 1 Division of Surgical Oncology, Department of Surgery; and the Human Immune Therapy Center, University of Virginia Comprehensive Cancer Center at the , Charlottesville, Virginia
17 shared publications - Emily K. Ninmer
University of Virginia 2 Charlottesville, Virginia
17 shared publications
Latest Publications
- Open Access
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Impact of GM-CSF and Two-Site Vaccination on Clinical Outcomes after Multipeptide Vaccination for Melanoma: Long-term Analysis of a Randomized Phase II Trial
Table S3. Immune response rates by treatment arm.
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Impact of GM-CSF and Two-Site Vaccination on Clinical Outcomes after Multipeptide Vaccination for Melanoma: Long-term Analysis of a Randomized Phase II Trial
Table S3. Immune response rates by treatment arm.
- Open Access
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Impact of GM-CSF and Two-Site Vaccination on Clinical Outcomes after Multipeptide Vaccination for Melanoma: Long-term Analysis of a Randomized Phase II Trial
Figure S5. Recurrence-free survival by duration of institutional follow-up.
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Impact of GM-CSF and Two-Site Vaccination on Clinical Outcomes after Multipeptide Vaccination for Melanoma: Long-term Analysis of a Randomized Phase II Trial
Figure S5. Recurrence-free survival by duration of institutional follow-up.
- Open Access
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Impact of GM-CSF and Two-Site Vaccination on Clinical Outcomes after Multipeptide Vaccination for Melanoma: Long-term Analysis of a Randomized Phase II Trial
Figure S3. Overall survival by selected participant characteristics.
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Impact of GM-CSF and Two-Site Vaccination on Clinical Outcomes after Multipeptide Vaccination for Melanoma: Long-term Analysis of a Randomized Phase II Trial
Figure S3. Overall survival by selected participant characteristics.
- Open Access
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Data S1 from Impact of GM-CSF and Two-Site Vaccination on Clinical Outcomes after Multipeptide Vaccination for Melanoma: Long-term Analysis of a Randomized Phase II Trial
Deidentified Participant Data File for Long-Term Outcomes of the Mel43 Clinical Trial
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data S1 from Impact of GM-CSF and Two-Site Vaccination on Clinical Outcomes after Multipeptide Vaccination for Melanoma: Long-term Analysis of a Randomized Phase II Trial
Deidentified Participant Data File for Long-Term Outcomes of the Mel43 Clinical Trial
- Open Access
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from Impact of GM-CSF and Two-Site Vaccination on Clinical Outcomes after Multipeptide Vaccination for Melanoma: Long-term Analysis of a Randomized Phase II Trial
Figure S6. Recurrence-free survival by selected participant characteristics
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from Impact of GM-CSF and Two-Site Vaccination on Clinical Outcomes after Multipeptide Vaccination for Melanoma: Long-term Analysis of a Randomized Phase II Trial
Figure S6. Recurrence-free survival by selected participant characteristics
- Open Access
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Impact of GM-CSF and Two-Site Vaccination on Clinical Outcomes after Multipeptide Vaccination for Melanoma: Long-term Analysis of a Randomized Phase II Trial
Figure S2. Overall survival by duration of institutional follow-up.
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Impact of GM-CSF and Two-Site Vaccination on Clinical Outcomes after Multipeptide Vaccination for Melanoma: Long-term Analysis of a Randomized Phase II Trial
Figure S2. Overall survival by duration of institutional follow-up.
- Open Access
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Impact of GM-CSF and Two-Site Vaccination on Clinical Outcomes after Multipeptide Vaccination for Melanoma: Long-term Analysis of a Randomized Phase II Trial
Figure S4. Recurrence-free survival by treatment arm
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Impact of GM-CSF and Two-Site Vaccination on Clinical Outcomes after Multipeptide Vaccination for Melanoma: Long-term Analysis of a Randomized Phase II Trial
Figure S4. Recurrence-free survival by treatment arm
- Open Access
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S7 from Impact of GM-CSF and Two-Site Vaccination on Clinical Outcomes after Multipeptide Vaccination for Melanoma: Long-term Analysis of a Randomized Phase II Trial
Table S7. Landmark multivariable analysis for recurrence-free survival by randomized arm.
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S7 from Impact of GM-CSF and Two-Site Vaccination on Clinical Outcomes after Multipeptide Vaccination for Melanoma: Long-term Analysis of a Randomized Phase II Trial
Table S7. Landmark multivariable analysis for recurrence-free survival by randomized arm.
- Open Access
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Impact of GM-CSF and Two-Site Vaccination on Clinical Outcomes after Multipeptide Vaccination for Melanoma: Long-term Analysis of a Randomized Phase II Trial
Table S4. Median survival time and rates by vaccine group
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Impact of GM-CSF and Two-Site Vaccination on Clinical Outcomes after Multipeptide Vaccination for Melanoma: Long-term Analysis of a Randomized Phase II Trial
Table S4. Median survival time and rates by vaccine group
- Open Access
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Impact of GM-CSF and Two-Site Vaccination on Clinical Outcomes after Multipeptide Vaccination for Melanoma: Long-term Analysis of a Randomized Phase II Trial
Figure S1. Overall survival by treatment arm
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Impact of GM-CSF and Two-Site Vaccination on Clinical Outcomes after Multipeptide Vaccination for Melanoma: Long-term Analysis of a Randomized Phase II Trial
Figure S1. Overall survival by treatment arm